Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

PaperCitations, authors & open-access status

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 71 citations, 2020 year and gold oa status.

71
Citations
2020
Year
gold
OA Status

Related on ScholarIQ

Jinxia Zhang
Author
Cancer Immunotherapy and Biomarkers
Topic
Cancer Immunotherapy and Biomarkers
Topic
Breast Cancer Treatment Studies
Topic
Advanced Breast Cancer Therapies
Topic
470M+ articles · free account